- cafead Dec 13, 2023 at 10:12: AM
via Another data face-off between the two anti-CD38 multiple myeloma drugs—Johnson & Johnson’s Darzalex and Sanofi’s Sarclisa—took place at the 65th American Society of Hematology meeting. Both regimens showed strong efficacy data in newly diagnosed patients, but only one result is considered practice-changing right now.
article source
article source